Payment overview · 2025
General Payments
$274.23
14 reported records · 8 companies
Healthcare provider profile · identity verified
Andre Dominick Tilton, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEW ORLEANS, LA · NPI 1306165097
Verified facts
What the public records show
CMS Open Payments records show Andre Dominick Tilton, MD received $274.23 in general payments during 2025 across 14 reported records.
Vanda Pharmaceuticals Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.80 | 22.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.73 | 18.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.38 | 18.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.45 | 14.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.33 | 8.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.61 | 6.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.74 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.19 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.23 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $61.80 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.38 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 427 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 91 |
| Tramadol Hcl | Tramadol Hcl | 282 | 52 |
| Gabapentin | Gabapentin | 278 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 41 |
| Meloxicam | Meloxicam | 164 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 54 |
| Omeprazole | Omeprazole | 138 | 32 |
| Ozempic | Semaglutide | 127 | 21 |
| Lisinopril | Lisinopril | 122 | 34 |
| Losartan Potassium | Losartan Potassium | 122 | 33 |
| Metformin Hcl | Metformin Hcl | 120 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 112 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 49 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 92 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 21 |
| Sertraline Hcl | Sertraline Hcl | 81 | 18 |
| Montelukast Sodium | Montelukast Sodium | 79 | 24 |
| Furosemide | Furosemide | 74 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 21 |
| Ibuprofen | Ibuprofen | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 19 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Mirtazapine | Mirtazapine | 60 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Atenolol | Atenolol | 57 | 15 |
| Clonazepam | Clonazepam | 56 | 15 |
| Trulicity | Dulaglutide | 56 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 16 |
| Topiramate | Topiramate | 50 | 13 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 29 |
| Azithromycin | Azithromycin | 48 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 21 |
| Promethazine Hcl | Promethazine Hcl | 44 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Carvedilol | Carvedilol | 40 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 40 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Linzess | Linaclotide | 38 | 12 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 11 |
| Glipizide | Glipizide | 36 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 16 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Baclofen | Baclofen | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.23 · 14 records | Vanda Pharmaceuticals Inc. | BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, FANAPT, LINZESS, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error